Natural Killer Cell

A study of 328 advanced NSCLC patients found 83 eligible for immunotherapy, with 56 achieving durable clinical benefit (DCB). Pre-treatment ctDNA and blood-based tumor mutational burden (bTMB) were higher in DCB patients. Early ctDNA dynamics, particularly a 50% decrease, strongly predicted DCB. Combining normalized bTMB, ctDNA dynamics, and RECIST response improved DCB prediction accuracy.

Affimed's acimtamig and AlloNK® combination showed 86% overall response and 55% complete response in 22 heavily pretreated R/R cHL patients, with a well-managed safety profile.

The FDA granted RMAT designation to Affimed's innate cell engager acimtamig and Artiva's AlloNK® for relapsed/refractory Hodgkin Lymphoma, based on an 83.3% overall response rate and 50% complete response rate in early efficacy data, with a well-managed safety profile.

Aulos Bioscience announced dosing of the first patient with AU-007, avelumab, and low-dose aldesleukin in a Phase 2 cohort for PD-L1+ NSCLC. This trial is a collaboration with Ares Trading S.A., a Merck KGaA subsidiary, and part of Aulos’ Phase 1/2 clinical trial of AU-007. Preliminary data from the Phase 2 cohort is expected in the first half of 2025.

LIfT BioSciences expands into Ireland with a new subsidiary in Galway, enhancing its global footprint and manufacturing capabilities. The expansion, supported by the University of Galway, HookeBio, and Údarás na Gaeltachta, positions LIfT for clinical trials of its allogeneic neutrophil-based immuno-cell therapy for solid tumours.

INmune Bio, Inc. completed randomization of patients for its Phase 2 AD02 trial on Nov. 11, focusing on Early AD and neuroinflammation. The trial, with 208 patients, aims to assess cognitive function changes after 24 weeks using XPro™, targeting glial cells to decrease neurodegeneration. Top-line results are expected in Q2 2025.

ImmunityBio reports Q3 2024 financials: ANKTIVA receives J-code, coverage secured for 200M lives, net product revenue $6M, shelf life extended to 3 years, UK and EU MAA submissions planned. Net loss $85.7M, cash and marketable securities $130.4M.

IMNN-001 immunotherapy plus chemotherapy improved overall survival by 35% and progression-free survival by 25% in advanced ovarian cancer patients. Treatment was well-tolerated, with no serious immune-related adverse events. IMUNON plans to initiate a Phase 3 trial in Q1 2025.

Ankyra Therapeutics has dosed the first patient with a visceral tumour in part two of its Phase I clinical trial of anchored interleukin-12 (IL-12), ANK-101. The trial aims to evaluate the new 'anchored therapy' in deep-seated solid tumours, ensuring prolonged drug retention in the tumour microenvironment to enhance local anti-tumour activity while minimising systemic toxicity. ANK-101, designed to stimulate local anti-tumour responses, is currently undergoing Phase I clinical trials in the US and Canada.

INmune Bio Inc. reports financial results for Q3 2024, including a net loss of $12.1 million. Highlights include completion of enrollment for Phase 2 Alzheimer’s Disease trial, interim analysis showing EMACC's exceptional performance, and INKmune™ demonstrating safety and increased NK-Cell activity in a Phase I/II trial for metastatic Castration-Resistant Prostate Cancer.